Given the therapeutic effects of SEC14L3 knockdown on ccRCC and its inhibition of the NFκB pathway, we investigated whether combining SEC14L3 downregulation with sunitinib treatment could improve outcomes. Here, SEC14L3 is linked to nonpapillary renal cell carcinoma.